Xerostomia Therapeutics Market By Product Category (Saliva Substitutes and Oral Moisturizers, Systemic Salivary Stimulants, Preventive Dental Therapies, Mechanical and Gustatory Stimulants, Emerging Salivary-Gland Restoration Therapies); By Etiology (Medication-Induced Xerostomia, Radiation-Induced Xerostomia, Sjögren-Associated Xerostomia, Other Systemic and Local Causes); By Product Form (Sprays and Rinses, Gels, Tablets and Capsules, Lozenges, Gums and Adhering Discs, Intraductal Investigational Therapies); By Distribution Channel (Retail Pharmacies and E-Commerce, Dental Clinics, Hospital and Specialist Care, Specialist Treatment Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Large Is the Xerostomia Therapeutics Market and What Is Fueling Its Expansion?  – (Updated On: 24-Aug-2026)

The Global Xerostomia Therapeutics Market was valued at USD 940 million in 2025 and is projected to reach USD 1.25 billion by 2032, expanding at a CAGR of 4.1% during 2026–2032, according to Strategic Market Research.

 

The Xerostomia Therapeutics Market is advancing as the need grows for effective solutions to manage chronic dry mouth caused by medications, radiation therapy, aging, and autoimmune disorders such as Sjögren's syndrome. Current treatment approaches mainly focus on improving oral moisture, stimulating remaining salivary gland function, and preventing complications such as tooth decay, infections, and difficulty swallowing. Artificial saliva products, moisturizing gels, oral rinses, hydration strategies, and dental protection measures provide supportive symptom management, particularly for patients with reduced saliva production.

 

Prescription therapies remain limited but clinically important. Drugs such as pilocarpine (Salagen) and cevimeline (Evoxac) stimulate muscarinic receptors to enhance saliva secretion in patients with functional gland capacity. However, these treatments primarily improve symptoms and do not restore damaged salivary tissue. This limitation is directing research toward regenerative approaches aimed at addressing the underlying causes of gland dysfunction.

 

The emerging pipeline includes advanced gene and cell therapies designed to repair or restore salivary gland activity. MeiraGTx is developing AAV2-hAQP1 gene therapy, which aims to improve water transport in damaged salivary glands and has received FDA Breakthrough Therapy and RMAT designations for radiation-induced xerostomia. Researchers at the University of Wisconsin/UW Health are also exploring stromal cell-based therapies to promote salivary gland recovery.

 

The addressable clinical burden is substantial, although prevalence differs according to how dry mouth is measured. A systematic review of population-based studies estimated overall dry-mouth prevalence at 22.0%, while a newer 2026 meta-analysis covering 174,698 participants aged 60 years or older estimated xerostomia prevalence at 32.4%, reinforcing the commercial relevance of aging populations and chronic medication use.

 

Overall, the market is shifting from temporary symptom relief toward regenerative medicine and disease-modifying treatments that could provide longer-lasting improvements in oral health and quality of life.

 

Key Xerostomia Therapeutics Market Insights Across Products, Etiologies, Forms, and Distribution Channels

By Product Category

• Saliva Substitutes and Oral Moisturizers: Sprays, gels, rinses and lozenges form the broadest repeat-use product category because they can be used irrespective of whether functional salivary tissue remains. This segment accounts for approximately 42% market share, with an estimated market size of USD 1.1 billion in 2025 and a projected CAGR of 6.8% through 2032.

• Systemic Salivary Stimulants: Pilocarpine and cevimeline occupy the prescription segment for patients with residual gland function, with efficacy balanced against sweating, gastrointestinal effects and pulmonary, ocular or cardiovascular precautions. This segment represents approximately 24% market share, with an estimated market size of USD 630 million in 2025 and a projected CAGR of 5.9% through 2032.

• Preventive Dental Therapies: High-fluoride toothpaste, fluoride gels and varnishes address the downstream caries burden associated with persistent loss of saliva and keep dentists central to xerostomia management. This segment holds approximately 18% market share, with an estimated market size of USD 470 million in 2025 and a projected CAGR of 6.4% through 2032.

• Mechanical and Gustatory Stimulants: Sugar-free gums, xylitol-containing lozenges and similar products provide accessible stimulation when some functional salivary capacity remains but compete directly with low-cost self-care measures. This segment accounts for approximately 11% market share, with an estimated market size of USD 290 million in 2025 and a projected CAGR of 5.6% through 2032.

• Emerging Salivary-Gland Restoration Therapies: Gene and RNA programs targeting aquaporin-1 represent the most strategically important pipeline segment because they aim to restore secretion rather than repeatedly replace oral moisture. This segment currently represents approximately 5% market share, with an estimated market size of USD 130 million in 2025 and a projected CAGR of 18.5% through 2032.

 

By Etiology

• Medication-Induced Xerostomia: The largest broad-based treatment pool is associated with chronic use of xerogenic medications and becomes increasingly relevant as medication counts rise in older populations. This segment represents approximately 46% market share, with an estimated market size of USD 1.2 billion in 2025 and a projected CAGR of 6.7% through 2032.

• Radiation-Induced Xerostomia: A smaller but high-severity segment supports specialist supportive-care products and is currently the principal target for advanced salivary-gland restoration programs. This segment accounts for approximately 22% market share, with an estimated market size of USD 580 million in 2025 and a projected CAGR of 8.9% through 2032.

• Sjögren-Associated Xerostomia: Chronic autoimmune destruction creates sustained use of prescription sialogogues, saliva substitutes and intensive preventive dental care. This segment holds approximately 19% market share, with an estimated market size of USD 500 million in 2025 and a projected CAGR of 7.4% through 2032.

• Other Systemic and Local Causes: Diabetes, neurological injury, chemotherapy, immunotherapy, mouth breathing and other conditions generate a heterogeneous treatment pool requiring primarily supportive management. This segment represents approximately 13% market share, with an estimated market size of USD 340 million in 2025 and a projected CAGR of 6.1% through 2032.

 

By Product Form

• Sprays and Rinses: Portable and familiar formats support frequent daytime use and broad retail distribution. This segment accounts for approximately 34% market share, with an estimated market size of USD 890 million in 2025 and a projected CAGR of 6.5% through 2032.

• Gels: Longer mucosal contact makes gels particularly relevant for persistent and nighttime dryness. This segment represents approximately 23% market share, with an estimated market size of USD 600 million in 2025 and a projected CAGR of 6.9% through 2032.

• Tablets and Capsules: Prescription oral sialogogues provide systemic stimulation but require medical assessment and monitoring. This segment holds approximately 24% market share, with an estimated market size of USD 630 million in 2025 and a projected CAGR of 5.9% through 2032.

• Lozenges, Gums and Adhering Discs: These formats combine mechanical or gustatory stimulation with prolonged oral contact and differentiate products through convenience and overnight use. This segment accounts for approximately 14% market share, with an estimated market size of USD 370 million in 2025 and a projected CAGR of 6.2% through 2032.

• Intraductal Investigational Therapies: AAV2-hAQP1 and RXRG001 are delivered directly to salivary glands, creating a specialist procedure-based model rather than a conventional retail product pathway. This segment currently represents approximately 5% market share, with an estimated market size of USD 130 million in 2025 and a projected CAGR of 18.5% through 2032.

 

By Distribution Channel

• Retail Pharmacies and E-Commerce: OTC moisturizers, sprays, gels, gums and lozenges benefit from self-directed purchasing and repeated consumption. This channel accounts for approximately 48% market share, with an estimated market size of USD 1.25 billion in 2025 and a projected CAGR of 6.6% through 2032.

• Dental Clinics: Dentists influence product recommendation while managing caries prevention, fluoride therapy and oral complications of persistent xerostomia. This channel represents approximately 24% market share, with an estimated market size of USD 630 million in 2025 and a projected CAGR of 6.8% through 2032.

• Hospital and Specialist Care: Oncology and rheumatology pathways account for patients with radiation injury, Sjögren disease and complex systemic disease. This channel holds approximately 20% market share, with an estimated market size of USD 520 million in 2025 and a projected CAGR of 7.9% through 2032.

• Specialist Treatment Centers: Emerging intraductal gene and RNA therapies would require more controlled delivery infrastructure than existing consumer or prescription products. This channel currently represents approximately 8% market share, with an estimated market size of USD 210 million in 2025 and a projected CAGR of 16.8% through 2032.

 

Clinical and Patient-Centric Forces Accelerating the Xerostomia Therapeutics Market

Medication exposure remains the broadest treatment generator. NIDCR states that hundreds of medicines can reduce salivary output, including therapies used for hypertension, depression and bladder-control disorders. This exposes the xerostomia market to prescription trends well outside dentistry and oral medicine.

Recent primary-care evidence provides a more commercial view of polypharmacy risk. A 2025 register-based study found that patients aged over 71 who were taking five or more medications had 9.68 times higher odds of xerostomia. Women represented 73.08% of diagnosed cases in that particular dataset. These figures should not be interpreted as global population shares—the 2023 England national oral-health survey, for example, found no significant sex difference—but they demonstrate how medication intensity and patient age can concentrate diagnosed treatment needs in routine care.

The U.S. Population Assessment of Tobacco and Health study adds another contemporary treatment indicator. Among 29,721 adults surveyed in 2022–2023, 9.7% reported dry mouth frequently or always. Daily cigarette, e-cigarette and cannabis use were each independently associated with higher odds of xerostomia.

Sjögren disease creates a more treatment-intensive population because gland dysfunction is chronic rather than a temporary medication effect. NIDCR estimates that Sjögren disease affects 1 million to 4 million people in the United States. Saliva substitutes and prescription drugs that increase saliva remain part of current management because there is no curative treatment for the underlying disease.

Cancer survivorship creates another commercially important pathway. Radiation can produce persistent structural damage to salivary glands, while chemotherapy-related oral effects are more frequently acute. SEER estimates 60,480 new oral cavity and pharynx cancer cases in the United States in 2026. Not every patient receives salivary-gland-damaging radiation, but continued treatment across the head-and-neck cancer therapeutics pathway replenishes the population at risk of long-lasting xerostomia.

 

Current Treatment Innovations, Market Trends, and Competitive Dynamics in Xerostomia Therapeutics

Saliva Substitutes and Oral Moisturizers

Topical products have the lowest clinical entry barrier because they do not depend on viable gland tissue. Carboxymethylcellulose, glycerin and related viscosity-enhancing ingredients are frequently used to retain moisture on oral surfaces. Products are differentiated by delivery format rather than by major therapeutic mechanism: sprays emphasize mobility, gels favor prolonged contact, rinses fit routine oral hygiene and lozenges or adhering discs extend residence time.

This segment also faces unusually strong substitution pressure. Water, humidification, sugar-free gum and inexpensive oral-care products can partially address symptoms. Branded manufacturers therefore need additional reasons for repeat purchase such as neutral pH, alcohol-free formulations, enamel protection, fluoride, xylitol, overnight duration or endorsement through dental channels. ADA guidance recognizes saliva substitutes as useful symptomatic therapy but does not identify a single topical formulation as universally superior.

Prescription Sialogogues

Pilocarpine has a wider U.S. labeled xerostomia footprint than cevimeline. Current labeling covers dry mouth caused by head-and-neck radiotherapy and Sjögren disease, while cevimeline is indicated for Sjögren-associated dry mouth. Both require residual functional salivary tissue to provide meaningful stimulation.

Tolerability restricts the commercial ceiling of systemic muscarinic stimulation. The updated British Society for Rheumatology guideline found significant improvements in oral dryness and salivary flow with pilocarpine but reported sweating in 43%, urinary frequency in 10% and flushing in 10% across cited trials. A comparative study reviewed in the guideline found similar efficacy between pilocarpine and cevimeline but less severe sweating with cevimeline, 11% versus 25%, and fewer treatment failures. Cevimeline is not available in the UK or Europe, leaving a geographic gap in systemic treatment choice.

Both drugs are contraindicated in uncontrolled asthma and in conditions where miosis is undesirable such as narrow-angle glaucoma. Significant cardiovascular disease is a caution requiring close supervision rather than an absolute contraindication. These restrictions create persistent use of non-systemic alternatives, particularly among older patients with multimorbidity.

Preventive Dental Therapy

Preventive dental care represents an important recurring revenue pathway in xerostomia because symptom relief does not restore saliva's protective effect against caries and infection. The ADA cites an estimated global xerostomia prevalence of about 22% and notes that virtually all patients receiving head-and-neck radiotherapy develop dry mouth. Its management recommendations include daily prescription-strength dental fluoride treatment, fluoride varnish and at least twice-yearly dental visits, extending treatment beyond saliva substitutes or stimulants.

This creates a commercially relevant attach opportunity around core xerostomia therapy. Patients using moisture products may also require fluoride formulations, professional varnish, dental surveillance and antifungal treatment. A meta-analysis found xerostomic patients had 2.48 times higher odds of oral candidiasis than controls, reinforcing continued use of dental consumables and professional management even when the primary dry-mouth product is purchased elsewhere.

 

Innovative Pipeline Developments Reshaping the Xerostomia Therapeutics Market

MeiraGTx — AAV2-hAQP1
AAV2-hAQP1 is the most clinically advanced salivary-gland restoration therapy in development, using an aquaporin-1 gene delivered into damaged parotid tissue to restore water transport rather than merely lubricate the mouth. In a 24-patient Phase 1 study of grade 2/3 late radiation-induced xerostomia, the therapy produced no treatment-related serious adverse events or dose-limiting toxicities, while 12-month results showed a 39.5% mean improvement in Xerostomia Questionnaire scores, a 112.5% increase in unstimulated whole salivary flow and clinically meaningful improvement in 16 patients. Its 276-participant Phase 2 AQUAx2 trial has completed enrollment across the United States, Canada and the UK, with a pivotal readout expected in Q2 2027 and a potential BLA submission targeted for mid-2027, although these remain company projections. MeiraGTx's agreement for up to USD 400 million from Oberland Capital further strengthens development and commercialization capacity, positioning AAV2-hAQP1 as a potential first-in-class restorative treatment within the wider gene therapy landscape. Its ultimate success will depend on confirming durability, safety and meaningful patient benefit in the pivotal study.

RiboX Therapeutics — RXRG001
RiboX is addressing radiation-induced xerostomia through RXRG001, a first-in-human circular RNA therapy that delivers aquaporin-1 via lipid nanoparticles directly into the parotid ducts. Its Phase I/IIa SPRINX-1 trial (NCT06714253), which is recruiting approximately 42 patients, begins with unilateral dose escalation before moving to randomized bilateral administration. Although the program is earlier than AAV2-hAQP1 and cannot yet demonstrate commercial superiority, its strategic significance is substantial: the emergence of two distinct gene- and RNA-based approaches targeting aquaporin-mediated salivary restoration validates gland regeneration as a developing therapeutic category with potential to move xerostomia treatment beyond lifelong symptomatic relief.

 

Leading Companies Shaping the Xerostomia Therapeutics Market Competitive Landscape

Haleon plc — Biotène
Haleon is a global consumer-health company whose Biotène franchise represents one of the most established consumer-oriented platforms in xerostomia management. Its portfolio spans oral rinse, moisturizing spray, Oralbalance gel, fluoride toothpaste and dry-mouth lozenges, enabling the brand to address diverse needs ranging from portable daytime relief and overnight lubrication to preventive dental care. Biotène's market strength lies in broad retail availability, repeat-use purchasing and differentiation across product formats rather than pharmacological stimulation of salivary glands. Haleon's 2026 commentary further identified medication-associated dry mouth as a growth opportunity, linking Biotène's use to rising polypharmacy and broader pharmaceutical-use trends.

Dentaid — Dentaid Xeros
Dentaid operates across professional and consumer oral healthcare, with its Dentaid Xeros portfolio addressing chronic dry mouth through a multi-format approach that includes toothpaste, mouthwash, moisturizing gel, spray and tablets. By combining betaine, allantoin, xylitol and fluoride for moisture retention and enamel protection with malic acid and xylitol to stimulate residual salivary function, the portfolio serves patients across different levels of xerostomia severity. This integrated positioning strengthens Dentaid's relevance in dental-professional care, broadens usage occasions and reduces reliance on any single product format.

Sunstar Group — GUM HYDRAL
Sunstar's GUM business serves both professional and consumer oral-health markets, with its GUM HYDRAL range offering toothpaste, spray and gel for xerostomia management. The toothpaste contains 1,450 ppm fluoride to support caries prevention, while the spray and gel provide moisturization for repeated daytime or nighttime use. Classified as a medical-device line in European professional materials, GUM HYDRAL differentiates itself by combining dry-mouth relief with routine dental protection, enabling dental professionals to recommend an integrated regimen rather than a single symptom-focused product.

GC Corporation — GC Dry Mouth Gel
GC is a dental-products company with strong distribution through professional dental channels, competing in a focused niche of the xerostomia therapeutics market. Its GC Dry Mouth Gel is sugar-free, alcohol-free and formulated with a neutral pH to coat and lubricate oral tissues while providing comfort without creating an acidic oral environment. Although its portfolio is narrower than those of multi-format consumer brands, GC benefits from close integration with dental practices, where the gel can be recommended alongside fluoride and other preventive products to help manage the elevated demineralization and caries risks associated with chronic dry mouth.

Quest Products LLC — OraCoat
Quest Products markets OraCoat oral-care products, with XyliMelts serving as its key xerostomia offering through an oral-adhering delivery system. These adhesive discs attach to the teeth or gums and gradually release 550 mg of xylitol over several hours, supporting both daytime and overnight use. By extending contact time and reducing the need for frequent reapplication, XyliMelts address a major limitation of sprays and rinses, particularly during sleep when salivary flow is lowest, positioning the brand as a differentiated option for sustained dry-mouth relief.

MeiraGTx Holdings plc
MeiraGTx is a clinical-stage genetic-medicines company with in-house development and manufacturing capabilities, led in xerostomia by AAV2-hAQP1, an investigational therapy for moderate-to-severe radiation-induced dry mouth. Supported by FDA Regenerative Medicine Advanced Therapy and Breakthrough Therapy designations, the program completed pivotal Phase 2 enrollment in Q2 2026 and is targeting patients whose salivary-gland damage leaves them dependent on lifelong supportive products. If late-stage trials confirm meaningful, durable improvements in salivary function and acceptable safety, MeiraGTx could move beyond the crowded OTC and generic prescription market and establish a higher-value restorative treatment category for radiation-induced xerostomia.

RiboX Therapeutics
RiboX is an early-stage RNA therapeutics company developing circular-RNA medicines, with RXRG001 as its lead xerostomia program. The investigational therapy encodes aquaporin-1 and is designed to restore salivary function in patients with radiation-induced xerostomia and hyposalivation. Currently being evaluated in the recruiting Phase I/IIa SPRINX-1 study, RXRG001 introduces a non-viral, circular-RNA approach to a market historically dominated by saliva substitutes, oral-care products and small-molecule sialogogues, positioning RiboX as an emerging challenger in salivary-gland restoration.

 

Regional Hotspots Shaping Xerostomia Therapeutics Market Growth and Adoption

North America accounted for an estimated 38% share of the Xerostomia Therapeutics Market, representing approximately USD 357.2 million in 2025, and is projected to expand at a CAGR of 3.7% during 2026–2032. North America has one of the most developed treatment environments because consumer dry-mouth products, generic prescription sialogogues, dental prevention and advanced clinical research coexist within the same market.

The region is also the center of current restorative-therapy development. MeiraGTx's pivotal study includes U.S. and Canadian sites, while RiboX is recruiting U.S. patients into SPRINX-1. FDA's accelerated-development designations for AAV2-hAQP1 further strengthen the region's importance for premium future therapies.

Europe accounted for an estimated 29% share of the Xerostomia Therapeutics Market, representing approximately USD 272.6 million in 2025, and is projected to grow at a CAGR of 3.9% during 2026–2032. England's 2023 Adult Oral Health Survey found that 4% of adults always experienced dry mouth and another 12% experienced it frequently. Among those aged 75 years and older, 27% reported dry mouth always or frequently.

Treatment availability differs from the U.S. Cevimeline is not currently available in the UK or Europe according to the current BSR guideline, giving pilocarpine greater importance within systemic therapy. UK reimbursement rules also restrict NHS prescribing of certain artificial-saliva products to defined conditions such as radiotherapy-associated xerostomia or sicca syndrome.

Asia Pacific accounted for approximately 24% of the global Xerostomia Therapeutics Market, representing USD 225.6 million in 2025, and is projected to expand at a CAGR of 4.8% during 2026–2032. The region combines large aging populations with established oral-care manufacturers and substantial self-pay consumer-health channels. A nationally representative Australian study reported xerostomia in 13.2% of adults, rising to 26.5% among those aged 75 years and older. Lower income, lack of dental insurance and unfavorable dental-visiting patterns were associated with higher prevalence.

Sunstar and GC provide the region with established dry-mouth product portfolios, while markets such as Japan, Australia, China and India differ considerably in dental access, reimbursement and consumer purchasing behavior. The combination of aging and medication exposure favors repeat-use OTC products, while access to advanced biologic treatments will depend more heavily on country-specific regulatory and specialist-care infrastructure.

Latin America accounted for approximately 5% of the global market, representing USD 47.0 million in 2025, and is projected to expand at a CAGR of 4.6% during 2026–2032. Latin American evidence points to a meaningful burden in older adults but also demonstrates why market estimates require careful population definition. A 2025 study using a representative sample of adults aged 60 years and older in Pelotas, southern Brazil, reported xerostomia prevalence of 36.7%. Polypharmacy was independently associated with higher prevalence. The result is useful for identifying an elderly treatment opportunity but should not be extrapolated as a national Brazilian prevalence estimate.

Middle East & Africa accounted for an estimated 4% market share, representing approximately USD 37.6 million in 2025, and is projected to grow at a CAGR of 4.3% during 2026–2032. Epidemiological evidence for the overall population is less standardized than in North America or Western Europe, so disease-specific cohorts provide more reliable signals than broad regional estimates. A 2026 Saudi Arabian study of 314 hemodialysis patients found xerostomia in 46.2%, demonstrating the high treatment need that can emerge in medically complex populations without implying an equivalent prevalence in the general population.

 

Xerostomia Therapeutics Market Outlook Through 2032

Near-term market activity will remain dominated by repeat-use products because most xerostomia originates from chronic medication exposure, systemic disease or lasting treatment-related gland injury. Saliva substitutes and oral moisturizers have low access barriers, while fluoride-based prevention adds recurring dental expenditure. Pilocarpine and cevimeline retain a defined prescription role but have little room for fundamental product differentiation after decades of clinical use.

The more significant market change is occurring in radiation-induced xerostomia. The 2026 peer-reviewed AAV2-hAQP1 results provide evidence that salivary flow and patient-reported symptoms can potentially be improved through direct salivary-gland intervention rather than continuous oral lubrication. Its pivotal Phase 2 outcome will therefore be relevant not only to MeiraGTx but to the commercial validity of gland-restoration therapy as a separate treatment class.

RiboX adds competitive pressure through an alternative circular-RNA platform, although its clinical program remains much earlier. Future differentiation will depend on durability, safety, degree of salivary-flow restoration, symptom improvement, procedure complexity, eligibility criteria and the feasibility of repeat administration rather than on mechanism alone.

 

Xerostomia Therapeutics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 940 Million
Revenue Forecast in 2032	USD 1.25 Billion
Overall Growth Rate	CAGR of 4.1% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million/Billion, CAGR (2026–2032)
Segmentation	By Product Category, By Etiology, By Product Form, By Distribution Channel, and By Geography
By Product Category	Saliva Substitutes and Oral Moisturizers, Systemic Salivary Stimulants, Preventive Dental Therapies, Mechanical and Gustatory Stimulants, Emerging Salivary-Gland Restoration Therapies
By Etiology	Medication-Induced Xerostomia, Radiation-Induced Xerostomia, Sjögren-Associated Xerostomia, Other Systemic and Local Causes
By Product Form	Sprays and Rinses, Gels, Tablets and Capsules, Lozenges, Gums and Adhering Discs, Intraductal Investigational Therapies
By Distribution Channel	Retail Pharmacies and E-Commerce, Dental Clinics, Hospital and Specialist Care, Specialist Treatment Centers
By Geography	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	United States, Canada, Mexico, United Kingdom, Germany, France, Italy, Spain, Netherlands, Sweden, Norway, China, Japan, India, South Korea, Australia, New Zealand, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa, and Other Countries
Market Drivers	Chronic medication exposure, aging populations, Sjögren disease, head-and-neck radiation, recurring use of saliva substitutes and preventive dental products, and development of gene-, RNA- and cell-based salivary-gland restoration therapies
Customization Option	Available upon request